NewAmsterdam Pharma (NAMS) Non-Current Assets (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Non-Current Assets data on file, last reported at $74.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 6626.69% year-over-year to $74.6 million; the trailing twelve-month figure through Mar 2026 stood at $267.5 million (up 5282.1% YoY), and the FY2025 full-year result was $93.6 million, up 7653.44% from the prior year.
• Non-Current Assets slipped to $74.6 million in Q1 2026, from $93.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $93.6 million in Q4 2025 to a low of $85139.6 in Q4 2022.
• A 5-year average of $30.2 million and a median of $1.3 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 8096.55% in 2022 and sank 98.5% in 2024, its largest moves.
• Tracing NAMS's Non-Current Assets over 5 years: stood at $85139.6 in 2022, then soared by 259.41% to $306000.0 in 2023, then jumped by 294.44% to $1.2 million in 2024, then jumped by 7653.44% to $93.6 million in 2025, then fell by 20.29% to $74.6 million in 2026.
• Business Quant data shows NAMS's Non-Current Assets at $74.6 million in Q1 2026, $93.6 million in Q4 2025, and $54.1 million in Q3 2025.